Here you go ... just had a rough crack at it by plotting the data points from the chart showing Relyvrio rate of decline.
Essentially, gradient ( rate of decline ) = Cohort 1 on 2mg dose = Relyvrio
All higher dosage results are vastly superior than Relvrio.
The line of best fit for Cohort 2, 10mg - well it's pretty much horizontal.
If I was diagnosed with MND today, I'm taking Monepantel @ 10mg per kg, and leaving Relyvrio in the cupboard.
Ann: Presentation - Phase 1 Top-Line Results, page-31
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $86.55M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 18.5¢ | $330.4K | 1.741M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4071 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 24580 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |